Bengaluru, September 24, 2025: Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced that it has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC).

Under the terms of the agreement, Glenmark obtains exclusive rights to develop and commercialize Trastuzumab Rezetecan (SHR-A1811) worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan. Glenmark will pay an upfront payment of US$18 million. Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion. Based on the net sales of Trastuzumab Rezetecan within the licensed territory, Glenmark will pay corresponding royalties to Hengrui.

“We are delighted to collaborate with Hengrui and build on the scientific momentum of SHR-A1811 as we continue expanding our oncology pipeline and leadership. This partnership aligns strongly with our strategy to bring differentiated, high-value therapies to patients and reinforces our commitment to advancing innovation in areas of significant unmet need,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Limited.

“Facing the major global challenge of cancer treatment, Hengrui has over the years accelerated the research and development of cutting-edge innovative therapies such as ADCs and is committed to addressing clinical treatment challenges and meeting unmet medical needs. This collaboration with Glenmark is a significant step in Hengrui’s ongoing strategy to deepen its presence in emerging markets. We look forward to working together to enhance the accessibility of innovative therapies and to bring new hope to patients in more countries and regions,” said Jo Feng, President of Hengrui Pharma.

Trastuzumab Rezetecan is Hengrui’s self-developed HER2-targeted ADC. In May 2025, it was approved in China for the treatment of adult patients with HER2 (ERBB2) activating mutations in unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. This is the first China-developed ADC approved for HER2-mutated NSCLC. In September 2025, the new indication for Trastuzumab Rezetecan in breast cancer was accepted by China’s NMPA for review and was included in the priority review program. To date, Trastuzumab Rezetecan has been included in the NMPA’s Breakthrough Therapy Designation list for nine indications, covering NSCLC, breast cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, and gynecologic malignancies.

Currently, Trastuzumab Rezetecan is actively advancing multiple clinical trials. In August 2025, Trastuzumab Rezetecan in combination with adebrelimab and chemotherapy obtained Orphan Drug Designation from the US FDA for gastric or gastroesophageal junction adenocarcinoma.

This collaboration marks a significant step forward in Glenmark’s focused oncology strategy, particularly in complex biologics. It reinforces Glenmark’s long-term commitment to delivering next-generation therapies across high-burden, underserved geographies.

The post Glenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

–        403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics. 

Bengaluru; March 7, 2025: Glenmark Foundation, the Corporate Social Responsibility arm of Glenmark Pharmaceuticals announced the completion of the 5^th edition of the Glenmark Nutrition Awards. Held in partnership with IDOBRO our process partner, UN Global Compact Network India, sustainability partner and IMPAct4Nutrition, eco-system partner. This initiative reaffirms Glenmark’s commitment to combating malnutrition through innovation, impact, and sustainability. The awards received an overwhelming response with over 403 entries from 22 states, covering 168 districts across the country.

An esteemed jury chaired by Dr Raju Jotkar MD, Senior Consultant at the Mother-Child Health & Nutrition Mission, Government of Maharashtra, Sonali Mukherjee, SBC Specialist, Mumbai India Country Office; and Dr Veena Yardi MSc, MPhil & PhD (Foods, Nutrition & Dietetics Associate Professor, College of Home Science, Nirmala Niketan provided invaluable insights on nutrition advocacy throughout the selection process.

The winners of the Glenmark Nutrition Awards 2025 are:

Rural NGO’s Category:  Baikunthapur Tarun Sangha, Sundarbans, West Bengal 

Urban NGO’s Category: SNEH Foundation, Pune, Maharashtra 

Other Category: Mahavir International Foundation Trust, Jaipur, Rajasthan 

All three organizations have been awarded a grant of INR 2,00,000 (Rupees Two lakhs) each to further their transformative projects in their respective districts.

Speaking at the occasion, Cheryl Pinto, Executive Director – Corporate Services, Glenmark Pharmaceuticals Ltd. said, “At Glenmark Foundation, we believe that healthy children are the foundation of a healthier world. Our commitment to nutrition reflects a long-term vision for societal well-being. This year’s award submissions showcased not just strategies for improving nutrition but also find sustainable, long-term solutions. Our winners have demonstrated that with vision, innovation and strategy, we can tackle malnutrition. The future we work toward is one where every child is nourished, and every community thrives in a sustainable world.” 

Karon Shaiva – Chief Impact Officer & MD, Idobro Impact Solutions, stated during the event, “The Glenmark Nutrition Awards is an important initiative that recognises efforts to improve nutrition. This year, the focus has been on Nutrition and sustainability, both of which are crucial for building resilient, healthy communities. The winners and finalists this year were selected based on programs that go beyond meeting current dietary needs to also ensuring that the systems for food production, distribution, and consumption are capable of supporting future generations. Glenmark Foundation’s more than decade-long partnership with IDOBRO has fostered an environment conducive to NGOs working in the maternal and child health space.

On the occasion, Dr. Raju Jotkar, Senior Consultant at the Mother-Child Health & Nutrition Mission, Government of Maharashtra, said, “ It was a pleasure to serve as a Grand Jury member, evaluating nine finalists from 403 entries using a well-structured framework that ensured fairness, transparency, and impact. The diverse geographical representation of awardees reflects the initiative’s authenticity and competitiveness. Given India’s nutritional transition and rising obesity concerns, future initiatives should also address overweight-related health risks, aligning with national efforts to combat non-communicable diseases. I sincerely hope this nutrition award initiative continues to strengthen India’s health and well-being.“

Glenmark Foundation has focused on malnutrition as a key issue, giving special attention to children aged 0 to 6 years, as well as pregnant and lactating mothers. Using a 360-degree approach to fighting malnutrition via different programs and interventions, the Glenmark Nutrition Awards aim to reaffirm the collective resolve to address malnutrition and promote holistic nutrition solutions across India’s diverse landscape.

The post Glenmark Nutrition Awards 2025: Celebrating Innovation, Impact, and Sustainability in the Fight Against Malnutrition in India  appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

According to IQVIA^TM sales data for the 12-month period ending December 2024, the Xalatan® Ophthalmic Solution, 0.005% market³ achieved annual sales of approximately $113.5 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of our 4^th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel. This addition highlights our commitment to meeting market needs and providing quality solutions for our customers.”

The post Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.